Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice

Journal of Clinical Investigation

Volumn 117, Issue 6, 2007, Pages 1514-1526

  Aihara, Ken Ichi ^a,b,c   Azuma, Hiroyuki ^a   Akaike, Masashi ^a   Ikeda, Yasumasa ^a,b   Sata, Masataka ^c   Takamori, Nobuyuki ^a   Yagi, Shusuke ^a   Iwase, Takashi ^a   Sumitomo, Yuka ^a   Kawano, Hirotaka ^c   Yamada, Takashi ^c   Fukuda, Toru ^c   Matsumoto, Takahiro ^c,d   Sekine, Keisuke ^c   Sato, Takashi ^c   Nakamichi, Yuko ^c   Yamamoto, Yoko ^c   Yoshimura, Kimihiro ^c   Watanabe, Tomoyuki ^c   Nakamura, Takashi ^c   Oomizu, Akimasa ^e   Tsukada, Minoru ^e   Hayashi, Hideki ^f   Sudo, Toshiki ^f   Kato, Shigeaki ^c,d   Matsumoto, Toshio ^a,b   more..

^a Department of Medicine and Bioregulatory Sciences ^*  (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e Benesis Corporation   (Japan)

^f OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE; CYTOKINE; HEPARIN COFACTOR II; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; FEMALE; GENE TARGETING; LETHALITY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; BASE SEQUENCE; BLOOD VESSELS; DNA PRIMERS; EMBRYO LOSS; FEMALE; GENE TARGETING; GENES, LETHAL; GENOTYPE; HEPARIN COFACTOR II; HETEROZYGOTE; HOMOZYGOTE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PREGNANCY;

EID: 34249905656     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27095     Document Type: Article

References (63)

1. Narayanan, S. 1999. Multifunctional roles of thrombin. Ann. Clin. Lab Sci. 29:275-280.
2. Bar-Shavit, R., Kahn, A., Wilner, G.D., and Fenton, J.W., 2nd. 1983. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science. 220:728-731.
3. Chen, L.B., and Buchanan, J.M. 1975. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc. Natl. Acad. Sci. U. S. A. 72:131-135.
4. McNamara, C.A., et al. 1993. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J. Clin. Invest. 91:94-98.
5. Derian, C.K., Damiano, B.P., D'Andrea, M.R., and Andrade-Gordon, P. 2002. Thrombin regulation of cell function through protease-activated receptors: implications for therapeutic intervention. Biochemistry Mosc. 67:56-64.
6. Griffin, C.T., Srinivasan, Y., Zheng, Y.W., Huang, W., and Coughlin, S.R. 2001. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science. 293:1666-1670.
7. Cheung, W.M., D'Andrea, M.R., Andrade-Gordon, P., and Damiano, B.P. 1999. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler. Thromb. Vasc. Biol. 19:3014-3024.
8. Nelken, N.A., et al. 1992. Thrombin receptor expression in normal and atherosclerotic human arteries. J. Clin. Invest. 90:1614-1621.
9. Sambrano, G.R., Weiss, E.J., Zheng, Y.W., Huang, W., and Coughlin, S.R. 2001. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 413:74-78.
10. Major, C.D., Santulli, R.J., Derian, C.K., and Andrade-Gordon, P. 2003. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 23:931-939.
11. Hirano, K., and Kanaide, H. 2003. Role of protease-activated receptors in the vascular system. J. Atheroscler. Thromb. 10:211-225.
12. Singh, R., et al. 2001. Role for tissue factor pathway in murine model of vascular remodeling. Circ. Res. 89:71-76.
13. Li, Y.H., et al. 2006. Thrombomodulin plays an important role in arterial remodeling and neointima formation in mouse carotid ligation model. Thromb. Haemost. 95:128-133.
14. Peng, L., Bhatia, N., Parker, A.C., Zhu, Y., and Fay, W.P. 2002. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler. Thromb. Vasc. Biol. 22:934-939.
15. Gerdes, C., Faber-Steinfeld, V., Yalkinoglu, O., and Wohlfeil, S. 1996. Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury. Arterioscler. Thromb. Vasc. Biol. 16:1306-1311.
16. de Agostini, A.I., Watkins, S.C., Slayter, H.S., Youssoufian, H., and Rosenberg, R.D. 1990. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J. Cell Biol. 111:1293-1304.
17. Tollefsen, D.M., Pestka, C.A., and Monafo, W.J. 1983. Activation of heparin cofactor II by dermatan sulfate. J. Biol. Chem. 258:6713-6716.
18. Tollefsen, D.M. 1995. Insight into the mechanism of action of heparin cofactor II. Thromb. Haemost. 74:1209-1214.
19. Rosenberg, L.C., et al. 1985. Isolation of dermatan sulfate proteoglycans from mature bovine articular cartilages. J. Biol. Chem. 260:6304-6313.
20. Choi, H.U., et al. 1989. Characterization of the dermatan sulfate proteoglycans, DS-PGI and DS-PGII, from bovine articular cartilage and skin isolated by octyl-sepharose chromatography. J. Biol. Chem. 264:2876-2884.
21. Shirk, R.A., Parthasarathy, N., San Antonio, J.D., Church, F.C., and Wagner, W.D. 2000. Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J. Biol. Chem. 275:18085-18092.
22. Kanagawa, Y., et al. 2001. Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site: HC II Tokushima. Thromb. Haemost. 85:101-107.
23. Takamori, N., et al. 2004. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation. 109:481-486.
24. Aihara, K., et al. 2004. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation. 109:2761-2765.
25. He, L., Vicente, C.P., Westrick, R.J., Eitzman, D.T., and Tollefsen, D.M. 2002. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J. Clin. Invest. 109:213-219. doi:10.1172/JCI200213432.
26. Wilcox, J.N., et al. 1994. Characterization of thrombin receptor expression during vascular lesion formation. Circ. Res. 75:1029-1038.
27. Takada, M., et al. 1998. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ. Res. 82:980-987.
28. Andrade-Gordon, P., et al. 2001. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharmacol. Exp. Ther. 298:34-42.
29. Sata, M., et al. 2002. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. 8:403-409.
30. Gutierrez, J., Ballinger, S.W., Darley-Usmar, V.M., and Landar, A. 2006. Free radicals, mitochondria, and oxidized lipids: the emerging role in signal transduction in vascular cells. Circ. Res. 99:924-932.
31. Kamp, P.B., and Ragg, H. 1999. Rapid changes in the exon/intron structure of a mammalian thrombin inhibitor gene. Gene. 229:137-144.
32. Villa, P., et al. 1999. Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Thromb. Haemost. 82:1011-1014.
33. Corral, J., et al. 2004. Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation. 110:1303-1307.
34. Delorme, M.A., Xu, L., Berry, L., Mitchell, L., and Andrew, M. 1998. Anticoagulant dermatan sulfate proteoglycan (decorin) in the term human placenta. Thromb. Res. 90:147-153.
35. Bellart, J., et al. 1998. Heparin cofactor II: a new marker for pre-eclampsia. Blood Coagul. Fibrinolysis. 9:205-208.
36. Giri, T.K., and Tollefsen, D.M. 2006. Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood. 107:2753-2758.
37. Tollefsen, D.M. 2002. Heparin cofactor II deficiency. Arch. Pathol. Lab. Med. 126:1394-1400.
38. Tollefsen, D.M. 2004. Does heparin cofactor II modulate atherosclerosis and restenosis? Circulation. 109:2682-2684.
39. Schillinger, M., et al. 2004. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Thromb. Haemost. 92:1108-1113.
40. Vu, T.K., Hung, D.T., Wheaton, V.I., and Coughlin, S.R. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 64:1057-1068.
41. Ishihara, H., et al. 1997. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature. 386:502-506.
42. Xu, W.F., et al. 1998. Cloning and characterization of human protease-activated receptor 4. Proc. Natl. Acad. Sci. U. S. A. 95:6642-6646.
43. Patterson, C., et al. 1999. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J. Biol. Chem. 274:19814-19822.
44. Kalmes, A., Vesti, B.R., Daum, G., Abraham, J.A., and Clowes, A.W. 2000. Heparin blockade of thrombin-induced smooth muscle cell migration involves inhibition of epidermal growth factor (EGF) receptor transactivation by heparin-binding EGF-like growth factor. Circ. Res. 87:92-98.
45. Takeya, H., Gabazza, E.C., Aoki, S., Ueno, H., and Suzuki, K. 2003. Synergistic effect of sphingosine 1-phosphate on thrombin-induced tissue factor expression in endothelial cells. Blood. 102:1693-1700.
46. Hoshi, S., Goto, M., Koyama, N., Nomoto, K., and Tanaka, H. 2000. Regulation of vascular smooth muscle cell proliferation by nuclear factor-kappaB and its inhibitor, I-kappaB. J. Biol. Chem. 275:883-889.
47. Dinarello, C.A. 1996. Biologic basis for interleukin-1 in disease. Blood. 87:2095-2147.
48. Shindo, T., et al. 2002. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 8:856-863.
49. Loppnow, H., and Libby, P. 1990. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J. Clin. Invest. 85:731-738.
50. Spinetti, G., et al. 2004. Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arterioscler. Thromb. Vasc. Biol. 24:1397-1402.
51. Isoda, K., et al. 2003. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation. 108:516-518.
52. Yoshizawa, T., et al. 1997. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16:391-396.
53. Sekine, K., et al. 1999. Fgf10 is essential for limb and lung formation. Nat. Genet. 21:138-141.
54. Kawano, H., et al. 2003. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U. S. A. 100:9416-9421.
55. Nakamichi, Y., et al. 2003. Chondromodulin I is a bone remodeling factor. Mol. Cell. Biol. 23:636-644.
56. Matsuda, Y., et al. 1992. Location of the mouse complement factor H gene (cfh) by FISH analysis and replication R-banding. Cytogenet. Cell Genet. 61:282-285.
57. Aihara, K., et al. 2004. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Biol. Chem. 279:35798-35802.
58. Giri, T.K., Ahn, C.W., Wu, K.K., and Tollefsen, D.M. 2005. Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler. Thromb. Vasc. Biol. 25:2689-2690.
59. Sata, M., et al. 2000. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J. Mol. Cell. Cardiol. 32:2097-2104.
60. Ikeda, Y., et al. 2005. Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis. J. Biol. Chem. 280:29661-29666.
61. Sata, M., Tanaka, K., Ishizaka, N., Hirata, Y., and Nagai, R. 2003. Absence of p53 leads to accelerated neointimal hyperplasia after vascular injury. Arterioscler. Thromb. Vasc. Biol. 23:1548-1552.
62. Yamanaga, K., et al. 2000. Heparin cofactor II inhibits thrombus formation in a rat thrombosis model. Thromb. Res. 98:95-101.
63. Zhou, J., Lhotak, S., Hilditch, B.A., and Austin, R.C. 2005. Activation of the unfolded protein response occurs at all stages of atherosclerotic lesion development in apolipoprotein E-deficient mice. Circulation. 111:1814-1821.